The Latest Breaking News from Hologic

Hologic has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s future.

Hologic is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth in the company’s bottom-line figure.

Hologic has recently outperformed in the Nasdaq, and Wall Street analysts are moderately bullish about the stock’s prospects.

Hologic is expected to report its third-quarter earnings results this month, and Wall Street analysts expect a single-digit profit growth.

FDA warns of complications with Hologic's soft tissue medical devices, urging vigilance and reporting.

Results have shown lower-earning women are less likely to receive preventative health care and more likely to give up work as a result of chronic pain

Women in households earning up to £25k per annum are less health literate - and less likely to understand healthcare professionals

The WTA is pushing for advancement in women’s healthcare through its partnership with Hologic

Upgrades

Pulled from Benzinga Pro data, Hologic (NASDAQ:HOLX) posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters.

Hologic Inc (NASDAQ:HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate for revenues of $1.29 billion. Lower sales of COVID-19 assays primarily drove a fall in sales. Hologic's global diagnostics business posted revenues of $987.1 million, down 7%. Diagnostics revenues excluding COVID-19 revenues…